MedTrace Logo

CNS Tau Kinetics in Healthy Aging and Alzheimer's Disease

NCT03938870 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 96

Last updated 2024-02-13

No results posted yet for this study

Summary

Alzheimer's disease (AD) is the most common cause of dementia and currently has no disease modifying treatments or simple accurate diagnostic tests. The goal of this project is to study how tau (a protein thought to cause AD) is made, transported and cleared in the human body. Better understanding of these processes may lead to improved understanding of AD, earlier diagnosis and a way to evaluate treatment.

Conditions

Interventions

OTHER

L-Leucine 13C6

Sponsors & Collaborators

  • BrightFocus Foundation

    collaborator OTHER

  • National Institutes of Health (NIH)

    collaborator NIH

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Randall Bateman, MD · Washington University in Saint Louis

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-08-18
Primary Completion
2023-07-06
Completion
2023-07-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03938870 on ClinicalTrials.gov